Posted by Michael Wonder on 23 Oct 2020
Decision to widen access to a brand of long-acting methylphenidate
23 October 2020 - PHARMAC is pleased to announce widening of access to one brand of extended-release methylphenidate, Methylphenidate ER – Teva, from 1 November 2020.
This means that the longer-acting Methylphenidate ER – Teva brand will be funded as a first-line treatment for attention deficit hyperactivity disorder alongside the shorter-acting versions of methylphenidate (immediate-release and sustained-release). This change results from a price reduction for Methylphenidate ER – Teva.
